Stay up to speed on: Healthcare Providers Medicare/Medicaid/CMS Policies & Regulations Healthcare Reform Healthcare Finance Click here to see a sample. We never sell or give away your contact information. Our readers’ trust comes first. But here’s one you might not have expected: We’re likely to also see a shortage of gastroenterologists. Why? Primarily because primary care physicians don’t provide colonoscopies. And colonoscopies are increasingly needed to catch cancer early, or even identify precancerous disease. Unless the number of gastroenterologists increases, even the current rate of screening won’t be able to be sustained. The Lewin Group found that current rates will require an additional 1,050 gastroenterologists by 2020 (on top of the current 10,390 practicing gastroenterologists in the United States). If the rates go up by 10 percent, the nation would need as many as 1,550 additional gastroenterologists by that time. To learn more about the study: – read this piece from The New York Times Related Articles:
Rheumatologists and Gastroenterologists are Reluctant to Prescribe Biosimilars for Indications in Which They Have Not Been Clinically Tested
According to Biosimilars Advisory Service: Physician Perspectives on Biologics in Immunology & Infectious Disease, a similar proportion of surveyed rheumatologists and gastroenterologists, 49 percent and 47 percent, respectively, say that indication extrapolation should be performed carefully because some patients might be more sensitive to minute differences between the brand and the biosimilar. Survey findings suggest that in order for gastroenterologists and rheumatologists to feel comfortable prescribing a biosimilar, a randomized, Phase III trial comparing the biosimilar to its reference brand would be required in all indications. This differs from regulatory guidance in the United States, Europe and Japan which states that indication extrapolation is permitted, as long as it is scientifically justified by the applicant. Surveyed gastroenterologists and rheumatologists are hesitant to adopt biosimilars unless these agents demonstrate robust clinical data, so incentives, like cost reduction, will be important to facilitate uptake, said Biosimilars Advisory Service Director, Andrew Merron, Ph.D. Despite the moderate uptake of biosimilars that we expect from these specialists, the sheer size of this market means that biosimilars for immune diseases will be the most lucrative class of biosimilars by 2021. The Physician Perspectives on Biologics in Immunology & Infectious Disease module of the Biosimilars Advisory Service offers extensive primary research with US, French and German gastroenterologists and rheumatologists to highlight the key expectations that will drive or constrain biosimilar adoption. Insights from surveyed gastroenterologists and rheumatologists provide a sound basis for annualized, brand-specific biosimilar sales forecasts for the TNF-alpha inhibitors, other major biologics used in immune diseases and pegylated interferon alpha products, which are all included in the module. Sales forecasts are provided through 2021 across the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, the United Kingdom and Japan). About BioTrends Research Group BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 321-9400 or http://www.bio-trends.com . BioTrends is a Decision Resources Group company. About Decision Resources Group Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at http://www.DecisionResourcesGroup.com .